Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...
Nebraska Medicine helps tens of thousands of patients every year, but one unique facility on campus can’t be found anywhere ...
A wireless implant helped patients with severe macular degeneration regain usable vision. The results point toward a new ...
ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
4d
EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review
EyePoint Pharmaceuticals (EYPT) just shared that its pivotal Phase 3 trial for DURAVYU in wet age-related macular degeneration has passed the second independent safety committee review. This marks a ...
Podcaster Joe Rogan has claimed on The Joe Rogan Experience that using red light therapy and vitamin supplements has improved ...
The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...
Teaming up with the Healey & AMG Center, Inflammasome will advance its oral ALS drug kamuvudine-9, known as K9, into early clinical testing.
GlobalData on MSN
Regeneron’s Eylea franchise boosted by pair of FDA approvals
Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication ...
Strategic Update and New Path to Value CreationPalm Beach Gardens, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback